readthroughSign in
Aug 4, 2026Trial update

Deciphera registers Phase 1 drug interaction study of vimseltinib with dabigatran

Deciphera Pharmaceuticals has registered a new Phase 1 trial examining whether vimseltinib affects P-glycoprotein substrate dabigatran in healthy men.

Deciphera Pharmaceuticals' only registry update this week is a newly listed early-stage pharmacokinetics study.

  • A Phase 1 open-label trial (NCT07744802) will test the effect of vimseltinib on pharmacokinetics of the P-glycoprotein substrate dabigatran in healthy male participants.1 The study is recruiting, with an estimated enrollment of 20 participants1 and a single U.S. site in Overland Park, Kansas.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.